Proactive investorsLogo Proactive Investors UK Website

Search field

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Epic & Msn data
Epic RENE
Time: 16:35:00
Mid Price: 5.48
Change Today: 0.00
Change % Today: 0.00
Fifty Two Week High: 8.08
Fifty Two Week Low: 4.13
Market Capital: 23.99
Period & price data
Period Price
Now: 5.48
3 Months ago:
6 Months ago:
1 Year ago:
Additional information
Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
Epic: RENE
News: Latest news
Web Site: ReNeuron
Other Articles: 22-02-201026-11-200916-11-2009

ReNeuron

ReNeuron is a leading, UK-based stem cell company. Our primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need.  We have received regulatory approval for a Phase I clinical trial in the UK with our lead ReN001 stem cell therapy for disabled stroke patients. Patient recruitment for this trial will commence shortly. We are also developing stem cell therapies for a number of other conditions, including peripheral arterial disease and diseases of the retina.

CLICK HERE FOR FULL ANLAYSIS OF RENEURON
Monday, November 16, 2009

ReNeuron Group presents positive pre-clinical data for CTX stem cell line therapy

company news image

Stem ReNeuron Group PLC (AIM: RENE) said it is presenting further positive pre-clinical efficacy data for its ReN009 stem cell therapy for peripheral arterial disease (PAD) at the American Heart Association (AHA) Scientific Sessions 2009 in Orlando, Florida, which will run until November 18.

The research was conducted by Professor Paolo Madeddu, chair of Experimental Cardiovascular Medicine and colleagues at the University of Bristol’s Heart Institute, and builds on earlier preliminary work conducted by that group.

In two studies, the researchers tested ReNeuron's lead CTX neural stem cell line, via intramuscular injection, in rats with restricted blood supply to the limbs (ischaemia). A range of doses were used across the studies, from 3,000 to 3 million cells per treatment. A significant and dose-dependent recovery of blood flow to the ischaemic limb was seen as soon as three days after administration, with significantly increased revascularisation of the damaged tissue after 21 days, as measured by increased capillary and arteriole density.  

PAD is a chronic and debilitating disease that progressively restricts blood flow in the limbs, causing cramping, chronic pain and in extreme cases, loss of limb. PAD is commonly associated with other conditions such as diabetes, obesity and stroke. At least 1 in 20 people over the age of 55 have some degree of PAD and it becomes more common with increasing age.

ReNeuron is developing its ReN009 therapy as a non-patient specific stem cell treatment for late-stage PAD, or critical limb ischaemia, in diabetic patients for whom PAD is a side-effect of their diabetes.

Further pre-clinical studies are currently in progress with ReN009, focusing on diabetic models and utilising the newly-developed frozen formulation of the CTX cell line which will be used in future clinical trials. The results of these further studies will be reported in early 2010.

In the meantime, ReNeuron has scheduled meetings within the next month with both the UK Medicines and Healthcare Regulatory Agency (MHRA) and the UK Gene Therapy Advisory Committee (GTAC) in order to discuss and agree certain aspects of the late pre-clinical development plan for the ReN009 therapy. Equivalent meetings are also planned with regulatory authorities in other territories, including the US, ahead of initial clinical trials expected to commence in 2011.

Commenting on the results of the study, Professor Madeddu said: "We are excited by these latest results using the CTX stem cell line, where we have successfully replicated, in a dose-dependent way, the results of a promising initial study in a recognised hind limb ischaemia model. We see real clinical potential in this cell line in ischaemia, where the angiogenic properties of the cell line appear to play a significant role in restoring blood flow in the affected region."

NewsNow icon AddThis Feed Button
Register here to be notified of future ReNeuron articles.

Other ReNeuron articles

More articles ►

Other ReNeuron news

More news ►

Investors interested in ReNeuron recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.